Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome
Authors:
- 1 July 2020
- journal article
- research article
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 41 (2) , 279-284
Abstract
Asprosin and subfatin are recently discovered two new hormones of adipocyte origin that play a role in the regulation of glucose metabolism. Polycystic ovary syndrome (PCOS) is a gynaecological syndrome presenting with energy turbulence. The aim of this study was to investigate whether asprosin and subfatin play a role in PCOS disease. Thirty participants with a diagnosis of PCOS and thirty control group participants were included in this case-control study. Hormone profiles of the participants (subfatin, asprosin, insulin, prolactin, thyroid-stimulating hormone (TSH), oestradiol (E2), follicle-stimulating hormone (FSH), luteinising hormone (LH), dehydroepiandrosterone sulphate (DHEA-SO4), lipid profiles [(total testosterone, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride, cholesterol)], fasting blood sugar (FBS) and high-sensitivity C-reactive protein (hs-CRP) values were measured. While the levels of asprosin, LDL and triglyceride, TSH, E2, FSH, LH, DHEA-SO4 were found to be significantly higher in patients with PCOS compared to controls (p = .005; p = .01), subfatin and HDL levels were found to be low. Significantly decreasing subfatin and increasing asprosin levels in circulation in PCOS may play a role in the etiopathology of this disease and that they may also be new candidate molecules in addition to classical laboratory parameters in the diagnosis and follow-up of PCOS in the future.Keywords
This publication has 35 references indexed in Scilit:
- Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with IrisinCells, 2019
- The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patientsScientific Reports, 2019
- The Possible Practical Implication of High CRP Levels in PCOSClinical Medicine Insights: Reproductive Health, 2019
- Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndromeGynecological Endocrinology, 2018
- Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokinesPLOS ONE, 2018
- Antimullerian Hormone as Indicator of Ovarian DysfunctionActa Endocrinologica (Bucharest), 2017
- State of the art paper Biochemistry of adipose tissue: an endocrine organArchives of Medical Science, 2013
- PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO‐II anovulation and association with metabolic factorsBJOG: An International Journal of Obstetrics & Gynaecology, 2006
- Cardiovascular risk in women with polycystic ovarian syndrome (PCOS)Journal of Clinical Pathology, 2005
- Increased C-Reactive Protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2004